Data supplement for Calabrese et al., Efficacy and Safety of Lumateperone for Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder: A Phase 3 Randomized Placebo-Controlled Trial. Am J Psychiatry (doi: 10.1176/appi.ajp.2021.20091339)

Additional Inclusion and Exclusion Criteria

For inclusion, patients must have had a body mass index (BMI) of 19−35, inclusive, and be willing and able to comply with study requirements. Patients of childbearing potential were required to use highly effective birth control for at least 2 weeks prior to randomization through the end-of-study follow-up. A lifetime history of at least 1 bipolar manic or mixed episode (for bipolar I) or hypomanic episode (for bipolar II) were required for inclusion.

Patients meeting any of the following criteria were excluded from the study: significant risk for suicidal behavior defined as answering "yes" on items 4 or 5 (suicidal ideation) of the C-SSRS within 6 months prior to screening or at baseline, 1 or more suicide attempts within 2 years prior to screening, a score of ≥4 on item 10 (suicidal thoughts) on the MADRS, or who is considered an imminent danger to themselves or others; pregnant or breastfeeding; history within 12 months of screening of a psychiatric diagnosis other than bipolar disorder including schizophrenia, anxiety disorders, feeding or eating disorder, primary diagnosis of obsessive-compulsive disorder, personality disorder, and moderate or severe substance use disorder (excluding nicotine); hallucinations, delusions, or other psychotic symptomatology attributable to a DSM-5 diagnosis other than bipolar disorder; hospitalization for mania within 30 days of screening; electroconvulsive therapy, vagal nerve stimulation, or repetitive trans-cranial magnetic stimulation within the last 5 years or >1 course of electroconvulsive therapy; a rapid cycler, defined as ≥ 6 major depressive, manic, hypomanic, or mixed episodes in the previous year; history of treatment resistance, defined as a lifetime history of treatment resistance without remission to ≥ 2 treatments approved for bipolar depression; current or planned treatment with cognitive or behavioral therapy or systematic psychotherapy; lifetime history of epilepsy, seizure, or convulsion; indication of drug or alcohol abuse at screening; prior participation in a study with lumateperone or exposure to any investigational product within 3 months of baseline; recent use of cytochrome P450 3A4 inhibitor or inducers, anxiolytic medications, drugs with psychotropic properties or significant central nervous system effects; clinically significant abnormalities in laboratory values or clinical findings at screening; recent history of cardiovascular, endocrine, hepatic, renal, pulmonary, gastrointestinal, neurological, metabolic, pheochromocytoma or malignancy that may be detrimental to the patient if participating in the study; or history of or current evidence of HIV, hepatitis B, or hepatitis C infection.

FIGURE S1. Patient disposition (CONSORT diagram)



[a] One patient who received placebo treatment did not have a valid pre-dose baseline assessment and at least one valid postbaseline assessment with the Montgomery-Åsberg Depression Rating Scale and was not included in the modified intent-to-treat population.